Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance rTMS vs Quetiapine in Treatment Resistant Depression
NCT07760168Phase 3Not yet recruiting
- Sponsor
- AIIMS New Delhi
- Start
- Aug 2026
- Primary completion
- Aug 2028
01
Overview
Phase 3, randomised, single-blind trial in treatment-resistant depression (TRD) (2 arms), sponsored by AIIMS New Delhi. Primary endpoint: Montgomery-Åsberg Depression Rating Scale at 12 weeks. Planned start Aug 2026; status: not yet recruiting.
02
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT07760168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07760168.